← Leaderboards
Arnold E Postlethwaite
University Of Tennessee Health Sci Ctr
$3,571,879
Attributed
$3,724,720
Total exposure
21
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$8,912,329 · 21
VA$0 · 2
By mechanism
P50$4,380,010 · 2
T32$1,091,083 · 1
R01$871,012 · 2
RC1$845,643 · 1
P30$807,599 · 1
N01$591,808 · 1
Top collaborators
- David D. Brand4 shared
- Edward F Rosloniec4 shared
- John M Stuart4 shared
- Andrzej T Slominski2 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Andrzej T Slominski$8,883,305
- Harry W Jarrett$4,827,076
- Rajendra Raghow$183,920
Others in their field
Top investigators on “Rheumatoid Arthritis”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Lionel B Ivashkiv · Hospital For Special Surgery$38,096,851
- Paul M. Ridker · Brigham And Women'S Hospital$34,275,148
- V Michael Holers · University Of Colorado Denver$28,178,502
- Michael B Brenner · Brigham And Women'S Hospital$26,598,289
- Betty Diamond · Feinstein Institute For Medical Research$20,428,564
Research focus
Rheumatoid ArthritisHuman SubjectHuman Therapy EvaluationCollagenClinical ResearchCytokineArthritisChronicResponseAffectAutoimmunityAutoimmune DiseasesMouse ModelImmune ResponseImmunityBaseOral ToleranceVitamin DSclerodermaRegulatory T-LymphocyteProductionMalignant NeoplasmsCellsMonocyte
Grant awards (49)
The Vitamin D-Gelsolin-S1P Axis in Rheumatoid Arthritis$0
I01 · FY2020 · VA · contact PI
The Vitamin D-Gelsolin-S1P Axis in Rheumatoid Arthritis$0
I01 · FY2019 · VA · contact PI
The Vitamin D-Gelsolin-S1P Axis in Rheumatoid Arthritis$0
I01 · FY2018 · VA · contact PI
The Vitamin D-Gelsolin-S1P Axis in Rheumatoid Arthritis$0
I01 · FY2017 · VA · contact PI
Program Project for Mechanisms and Treatment of Arthritis$0
IP1 · FY2016 · VA
Program Project for Mechanisms and Treatment of Arthritis$0
IP1 · FY2015 · VA
Mechanism of action of 20-hydroxyvitamin D3 in dermal fibroblasts$5,682
R21 · FY2014 · AR
Program Project for Mechanisms and Treatment of Arthritis$0
IP1 · FY2014 · VA
Novel Biosynthethic Pathway for Secosteroids and the Skin$300,000
R01 · FY2013 · AR
Program Project for Mechanisms and Treatment of Arthritis$0
IP1 · FY2013 · VA
Chronic Sleep Restriction Increases Immunity to Autoantigen: Role of the SNS$418,375
RC1 · FY2010 · AR · contact PI
Chronic Sleep Restriction Increases Immunity to Autoantigen: Role of the SNS$427,268
RC1 · FY2009 · AR · contact PI
Research Training in Connective Tissue Diseases$179,706
T32 · FY2008 · AR · contact PI
Research Training in Connective Tissue Diseases$183,522
T32 · FY2007 · AR · contact PI
Rheumatic Disease Research Core Center$255,500
P30 · FY2006 · AR · contact PI
Research Training in Connective Tissue Diseases$133,817
T32 · FY2006 · AR · contact PI
OPEN LABEL MULTICENTER TRIAL OF ORAL CII TOLERANCE IN RA$51,302
M01 · FY2006 · RR · contact PI
CL CHANNEL ACTIVITY AND FUNCTION IN SYSTEMIC SCLEROSIS MYOFIBROBLASTS$5,188
M01 · FY2006 · RR · contact PI
ONE YEAR STUDY OF BOVINE TYPE I COLLAGEN VS PLACEBO IN SSC$2,306
M01 · FY2006 · RR · contact PI
SCOR on the Pathogenesis of Scleroderma$909,677
P50 · FY2005 · AR
Rheumatic Disease Research Core Center$552,099
P30 · FY2005 · AR
Research Training in Connective Tissue Diseases$86,898
T32 · FY2005 · AR
OPEN LABEL MULTICENTER TRIAL OF ORAL CII TOLERANCE IN RA$68,722
M01 · FY2005 · RR
ONE YEAR STUDY OF BOVINE TYPE I COLLAGEN VS PLACEBO IN SSC$8,085
M01 · FY2005 · RR
SCOR on the Pathogenesis of Scleroderma$889,377
P50 · FY2004 · AR
Research Training in Connective Tissue Diseases$112,487
T32 · FY2004 · AR
Pathogenic Mechanisms of Fibrosis:Common Ground$20,000
R13 · FY2004 · AR
Open Label Multicenter Trial of Oral CII Tolerance in RA$15,894
M01 · FY2004 · RR
One Year Study of Bovine Type I Collagen vs. Placebo in SSc$4,087
M01 · FY2004 · RR
Oral Administration of Lower Doses of Type I Bovine Collagen to Patients w/ Ssc$908
M01 · FY2004 · RR
SCOR on the Pathogenesis of Scleroderma$870,959
P50 · FY2003 · AR
Sleep Fragmentation Effects on Murine CII-Induced AR$71,500
R21 · FY2003 · AR
SCOR on the Pathogenesis of Scleroderma$848,723
P50 · FY2002 · AR
RESEARCH TRAINING IN CONNECTIVE TISSUE DISEASES$104,219
T32 · FY2002 · AR
Sleep Fragmentation Effects on Murine CII-Induced AR$71,500
R21 · FY2002 · AR
Outgrowth of fibroblastlike cells from PBMC cell culture$0
P50 · FY2002 · AR
SCOR on the Pathogenesis of Scleroderma$861,274
P50 · FY2001 · AR
CII ORAL TOLERANCE INDUCTION IN RA PATIENTS OFF NSAIDS$289,596
R01 · FY2001 · AR
RESEARCH TRAINING IN CONNECTIVE TISSUE DISEASES$148,976
T32 · FY2001 · AR
PAMIDRONATE TRIAL IN AIDS WASTING SYNDROME PATIENTS$0
M01 · FY2001 · RR
Outgrowth of fibroblastlike cells from PBMC cell culture$0
P50 · FY2001 · AR
Collagen II Oral Tolerance in Rheumatoid Arthritis$0
M01 · FY2001 · RR
ORAL TYPE II COLLAGEN &MISOPROSTOL TREATMENT OF RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
MULTI-CNTER PHASE 2 TRIAL OF ORAL TYPE I BOVINE COLLAGE$591,808
N01 · FY2000 · AR
CII ORAL TOLERANCE INDUCTION IN RA PATIENTS OFF NSAIDS$281,416
R01 · FY2000 · AR
RESEARCH TRAINING IN CONNECTIVE TISSUE DISEASES$141,458
T32 · FY2000 · AR
PAMIDRONATE TRIAL IN AIDS WASTING SYNDROME PATIENTS$0
M01 · FY2000 · RR
Collagen II Oral Tolerance in Rheumatoid Arthritis$0
M01 · FY2000 · RR
ORAL TYPE II COLLAGEN &MISOPROSTOL TREATMENT OF RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR